Novo Nordisk (NOVA) Price & Analysis

Compare

147 Followers

NOVA Stock Chart & Stats

€39.95

€2.60(3.26%)

At close: Jan 08 4:00 PM EST

€39.95

€2.60(3.26%)

Day’s Range― - ―

52-Week Range€36.10 - €90.40

Previous CloseN/A

Volume1.40K

Average Volume (3M)6.27K

Market Cap

€175.62B

Enterprise Value€1.42T

Total Cash (Recent Filing)€26.96B

Total Debt (Recent Filing)€130.96B

Price to Earnings (P/E)12.9

Beta0.95

Next Earnings

May 06, 2026

EPS Estimate

0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.81

Shares Outstanding3,390,128,000

10 Day Avg. Volume6,312

30 Day Avg. Volume6,269

Financial Highlights & Ratios

PEG Ratio8.17

Price to Book (P/B)7.42

Price to Sales (P/S)4.84

P/FCF Ratio25.38

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€48.07

Price Target Upside20.32% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Management Focus On ExecutionNew CEO emphasis on stronger commercial execution and a refocused strategy on obesity and diabetes may improve launch effectiveness and operational discipline.

Oral Semaglutide Commercial LaunchA large promotional push and relaunch efforts for the oral semaglutide pill are expected to drive patient adoption and help recover commercial momentum.

Pipeline Clinical ReadoutsPositive late-stage trial readouts for programs such as the diabetes candidate CagriSema and pivotal ziltivekimbab studies could deliver significant upside if they support regulatory approvals.

Bears Say

Competitive Market Share ErosionIntense competition from rival oral and next-generation obesity and diabetes treatments is expected to continue eroding market share for existing products.

Compounded Low-cost CompetitorsA low-cost compounded oral version of the pill from compounding pharmacies could undercut sales by offering a cheaper alternative despite questions about bioavailability.

Pricing And Channel PressuresContinued pricing declines caused by shifts in channel mix, government pricing rules, and increased cash-pay adoption are likely to weigh on revenue and margins.

Novo Nordisk News

Moderately bullish activity in Novo Nordisk with shares up 3.85%

Moderately bullish activity in Novo Nordisk (NVO), with shares up $1.83, or 3.85%, near $49.48. Options volume relatively...

52m ago

NVO

FDA warns Novo Nordiskover ‘misleading’ Wegovy ad

The Food and Drug Administration, in a letter to Novo Nordisk (NVO), said the company’s TV advertisement for...

6h ago

NVO

Morning Movers: Hims & Hers drops after deciding to stop selling Wegovy copycat

Equity futures edged slightly lower Monday as investors await the January jobs report and inflation data, as well...

8h ago

Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans

Hims & Hers (HIMS) said in a post on X, formerly Twitter: “Novo Nordisk’s (NVO) lawsuit is a...

8h ago

NVO

HIMS

Novo Nordisk sues Hims & Hers over Wegovy pill, injection copycats, CNBC reports

Novo Nordisk (NVO) is suing Hims & Hers (HIMS) for mass marketing cheaper, unapproved copies of the drugmaker’s...

9h ago

NVO

HIMS

Hims & Hers price target lowered to $21 from $26 at BofA

BofA analyst Allen Lutz lowered the firm’s price target on Hims & Hers to $21 from $26 and...

10h ago

LLY

NVO

HIMS Stock Drops, NVO Jumps after Hims & Hers Halts Selling $49 Wegovy Copy

Hims & Hers ($HIMS) stock hit a 52-week low of $21.12 on February 6, while Novo Nordisk ($NVO)...

12h ago

LLY

NVO

Hims & Hers (HIMS) Shares Sink 16% as FDA Crackdown Halts Wegovy Copycat Pill

Hims and Hers Health Inc. ($HIMS) has decided to stop selling a copycat version of Novo Nordisk’s ($NVO)...

1d ago

LLY

NVO

The Week That Was, The Week Ahead: Macro and Markets, Feb. 8

Despite a bloody week for tech stocks and crypto, U.S. stocks ended the week on a high note...

2d ago

FDA intends to ‘take action’ against non-FDA-approved GLP-1 drugs

The U.S. Food and Drug Administration announced its intent to take decisive steps to restrict GLP-1 active pharmaceutical...

3d ago

LLY

NVO

Why Hims & Hers (HIMS) Stock Is Falling despite the $49 Weight-Loss Pill Buzz

Shares of Hims & Hers Health ($HIMS) fell more than 3% in early trading today after the company’s...

3d ago

LLY

NVO

Eli Lilly Stock (LLY) Rebounds After FDA Says It Will Crackdown on Weight-Loss Drug Copies

Compounded medicines are a problem for pharma companies. ...

3d ago

LLY

NVO

Trump Trade: Argentina says U.S. to cut hundreds of tariffs

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

3d ago

AZN

FDA threatens action against ‘illegal copycat drugs,’ Reuters says

The U.S. FDA commissioner Marty Makary recently said the FDA will be taking action against companies producing “illegal...

3d ago

NVO

HIMS

NOVA FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was €36.10 and its highest was €90.40 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is €175.62B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is May 06, 2026 which is in 86 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Feb 04, 2026. The company reported €0.807 earnings per share for the quarter, beating the consensus estimate of €0.781 by €0.026.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk does not currently pay dividends.

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.7.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of €0.807 in its last earnings report, beating expectations of €0.781. Following the earnings report the stock price went down -6.11%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in DE:NOVA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Novo Nordisk Stock Smart Score

Underperform

Fundamentals

Return on Equity

61.25%

Trailing 12-Months

Asset Growth

31.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (NOVA) Earnings & Revenues

Historic Earnings Reports

NOVA Company Deck

NOVA Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call presented a mixed picture: strong commercial momentum in obesity and GLP-1 franchises (notably the successful Wegovy pill launch, robust GLP-1 volume share, and meaningful R&D readouts such as CagriSema and zenagamtide) alongside solid cash generation and shareholder returns. Offsetting these positives are substantial near-term headwinds driven by pricing pressure, policy impacts (MFN/MFP), loss of exclusivity risk, margin compression and a conservative 2026 outlook (adjusted sales and operating profit guidance of -5% to -13% CER). Management is bullish on long-term market expansion and pipeline potential but explicit near-term guidance and exceptional costs temper the tone. Overall, positives (product launches, R&D wins, market leadership and cash generation) are significant, but the company has signaled a pronounced near-term earnings challenge driven by pricing and policy — producing a balanced, watchful outlook.View all DE:NOVA earnings summaries

NOVA Stock 12 Month Forecast

Average Price Target

€48.07

▲(20.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"€34","85":"€85","46.75":"€46.8","59.5":"€59.5","72.25":"€72.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59.2073825,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€59.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.0679363925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€48.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.5244295,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.52</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,46.75,59.5,72.25,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50,50.70826019230769,51.41652038461538,52.12478057692308,52.83304076923077,53.54130096153846,54.24956115384615,54.95782134615385,55.66608153846154,56.37434173076923,57.08260192307692,57.79086211538462,58.49912230769231,{"y":59.2073825,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50,49.8513797225,49.702759445,49.5541391675,49.40551889,49.2568986125,49.108278335,48.9596580575,48.81103778,48.6624175025,48.513797225000005,48.365176947500004,48.21655667,{"y":48.0679363925,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50,48.88649457692308,47.772989153846154,46.65948373076923,45.54597830769231,44.432472884615386,43.31896746153846,42.20546203846153,41.09195661538462,39.97845119230769,38.86494576923077,37.75144034615384,36.63793492307692,{"y":35.5244295,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":79.788,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.885,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.103,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.738,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.333,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.567,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >